Skip to main content
Premium Trial:

Request an Annual Quote

Biodesix Raises $8.6M

NEW YORK (GenomeWeb) – Cancer diagnostics firm Biodesix has raised $8.6 million in promissory notes, according to a document filed recently with the US Securities and Exchange Commission.

The firm disclosed that it seeks to raise up to $20 million and that it has so far raised $8.6 million in promissory notes convertible into equity securities.

The firm did not disclose what it would use the funds for or the identities of the investors in the financing. It said that 18 investors have participated in the financing. Biodesix did not respond to requests seeking comment.

In June, the Boulder, Colorado-based firm raised $11 million in private follow-on financing to fund new product development and expand commercialization of the VeriStrat protein test and GeneStrat mutation test. In January, the firm closed a $27 million Series E financing round.